secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001437749-25-038835
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals eliminates all balance sheet debt by converting $5.4M to equity
--------------------------------------------------------------------------------

- Repaid remaining $5.4M debt to Anson Funds via equity conversion of common stock; no warrants or repricing mechanisms.
- Original Anson loan was $16.2M; Company expects Dec 31 balance sheet to reflect zero convertible debt.
- Debt-free capital structure positions NRx for accelerated growth with potential 2026 drug approvals and clinic expansions.
- Press release dated Dec 2, 2025; Debt Cancellation Agreement executed Dec 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925038835/0001437749-25-038835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925038835/nrxp20251229_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer